Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 2/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301707 | 1.00 | METTL3 (0.49) | METTL3PDE10AGSK3BKMT2AAURKA | |
| SCHEMBL1301270 | 0.94 | METTL3 (0.47) | METTL3PDE10AGSK3BKMT2AHDAC6 | |
| SCHEMBL1301276 | 0.94 | METTL3 (0.47) | METTL3PDE10AGSK3BKMT2AHDAC6 | |
| SCHEMBL1301826 | 0.93 | METTL3 (0.45) | METTL3GSK3BP2RX7GPR6 | |
| SCHEMBL1301823 | 0.93 | METTL3 (0.45) | METTL3GSK3BP2RX7GPR6 | |
| SCHEMBL1301788 | 0.92 | METTL3 (0.59) | METTL3GSK3BCD38 | |
| SCHEMBL1301791 | 0.92 | METTL3 (0.59) | METTL3GSK3BCD38 | |
| SCHEMBL1300924 | 0.91 | METTL3 (0.46) | METTL3PDE10AGSK3BKMT2AKDM4E | |
| SCHEMBL1300920 | 0.91 | METTL3 (0.46) | METTL3PDE10AGSK3BKMT2AKDM4E | |
| SCHEMBL1301311 | 0.90 | METTL3 (0.45) | METTL3PDE10AGSK3BSTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PDE10A 2011/4885GSK3B 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.